Affiliation:
1. Shanghai Pancreatic Cancer Institute, Shanghai, China
Abstract
Background:
Awareness of the benefits of neoadjuvant therapy is increasing, but its use as an
initial therapeutic option for patients with resectable pancreatic cancer remains controversial, especially
for those patients without high-risk prognostic features. Even for patients with high-risk features who are
candidates to receive neoadjuvant therapy, no standard regimen exists.
Methods:
In this review, we examined available data on the neoadjuvant therapy in patients with resectable
pancreatic cancer, including prospective studies, retrospective studies, and ongoing clinical trials,
by searching PubMed/MEDLINE, ClinicalTrials.gov, Web of Science, and Cochrane Library. The characteristics
and results of screened studies were described.
Results:
Retrospective and prospective studies with reported results and ongoing randomized studies were
included. For patients with resectable pancreatic cancer, neoadjuvant therapy provides benefits such as
increased survival, decreased risk of comorbidities and mortality, and improved cost-effectiveness due to
an increased completion rate of multimodal treatment. Highly active regimens such as FOLFIRINOX (folinic
acid, fluorouracil, irinotecan, and oxaliplatin) or gemcitabine plus nab-paclitaxel are considered acceptable
therapeutic regimens. Additionally, platinum-containing regimens other than FOLFIRINOX are
acceptable for selected patients. Other therapies, such as chemoradiation treatment, immuno-oncology
agents, and targeted therapies are being explored and the results are highly anticipated.
Conclusion:
This review highlights the benefits of neoadjuvant therapy for resectable pancreatic cancer.
Some regimens are currently acceptable, but need more evidence from well-designed clinical trials or
should be used after being carefully examined by a multidisciplinary team.
Funder
Yang-Fan Plan for Young Scientists of Shanghai, Science and Technology Commission of Shanghai Municipality
National Natural Science Foundation of Shanghai
National Natural Science Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry
Reference73 articles.
1. Lewis D.R.; Chen H.S.; Cockburn M.G.; Wu X.C.; Stroup A.M.; Midthune D.N.; Zou Z.; Krapcho M.F.; Miller D.G.; Feuer E.J.; Early estimates of SEER cancer incidence, 2014. Cancer 2017,123(13),2524-2534
2. Kamisawa T.; Wood L.D.; Itoi T.; Takaori K.; Pancreatic cancer. Lancet 2016,388(10039),73-85
3. NCCN clinical practice guidelines in oncology. Pancreatic adenocarcinoma. Version 2, 2017. Available at:
ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf">http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf (Accessed Date: 29 March, 2017).
4. Khorana A.A.; Mangu P.B.; Berlin J.; Engebretson A.; Hong T.S.; Maitra A.; Mohile S.G.; Mumber M.; Schulick R.; Shapiro M.; Urba S.; Zeh H.J.; Katz M.H.G.; Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2017,35(20),2324-2328
5. Seufferlein T.; Bachet J.B.; Van, Cutsem, E.; Rougier, P. Pancreatic adenocarcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012,23(Suppl. 7),vii33-vii40
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献